2 news items
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
KZIA
1 May 24
selective small molecule VEGFR3 tyrosine kinase inhibitor targeting tumour angiogenesis. Unlike traditional angiokinase inhibitors, we believe based
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
ACB
AGS
AIH
5 Apr 24
coverage on Ardelyx with an Outperform rating and announced a price target of $14.
Yatsen Holding Limited
- Prev
- 1
- Next